BACKGROUND:In clinical practice, an adapted regimen with dose reduction is applied to castration-resistant prostate cancer (CRPC) treated with docetaxel because of its toxicity.
However, there are few reports on the impact of dose reduction on survival.
METHODS:Fifty-seven patients with CRPC treated with first-line docetaxel in a single institution from 2005 to 2008 were evaluated retrospectively.
RESULTS: The median follow-up period was 20.5 months. Twenty-eight patients (49 %) received a standard 60 mg/m2regimen (SR), and 29 patients (51 %) received an adapted regimen (AR) with dose reduction. There was no difference in their baseline characteristics. The prostate-specific antigen response rates were not significantly different between the SR and AR groups (50 vs. 62 %, p = 0.36). Progression-free survival (PFS) and overall survival (OS) were also not significantly different between the groups (PFS 5.3 vs. 7.3 months, p = 0.39; OS 26.4 vs. 27.1 months, p = 0.53, respectively). No significant difference in the incidence of grade 3 or 4 adverse events was noted between the groups (89 vs. 83 %, p = 0.70). In multivariate analysis, hemoglobin and alkaline phosphatase were significant predictive factors for OS (hazard ratios 2.81 and 2.39, p = 0.012 and 0.024, respectively).
CONCLUSIONS: A reduced-dose regimen of docetaxel has no inferior impact on OS. Further studies on the optimal dose of docetaxel for Japanese patients are required.
Written by:
Kita Y, Shimizu Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. Are you the author?
Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Reference: Int J Clin Oncol. 2012 Jul 13. Epub ahead of print.
doi: 10.1007/s10147-012-0443-3
PubMed Abstract
PMID: 22791141
UroToday.com Prostate Cancer Section
